{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:37:44Z","timestamp":1790030264600,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00259-019-04581-4","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T20:01:20Z","timestamp":1573848080000},"page":"632-641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-9021","authenticated-orcid":false,"given":"Cem","family":"Onal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan Cem","family":"Guler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nese","family":"Torun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Reyhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Fuat","family":"Yapar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"4581_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330. https:\/\/doi.org\/10.3322\/caac.21442.","journal-title":"CA Cancer J Clin"},{"key":"4581_CR2","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/s1470-2045(10)70223-0","volume":"11","author":"M Bolla","year":"2010","unstructured":"Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11:1066\u201373. https:\/\/doi.org\/10.1016\/s1470-2045(10)70223-0.","journal-title":"Lancet Oncol"},{"key":"4581_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0360-3016(00)01516-9","volume":"49","author":"CA Lawton","year":"2001","unstructured":"Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;49:937\u201346.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4581_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3109\/07357909509024889","volume":"13","author":"JD Forman","year":"1995","unstructured":"Forman JD, Kumar R, Haas G, Montie J, Porter AT, Mesina CF. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Investig. 1995;13:8\u201315.","journal-title":"Cancer Investig"},{"key":"4581_CR5","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1259\/bjr\/65939531","volume":"82","author":"C Onal","year":"2009","unstructured":"Onal C, Topkan E, Efe E, Yavuz M, Arslan G, Yavuz A. The effect of concurrent androgen deprivation and 3D conformal radiotherapy on prostate volume and clinical organ doses during treatment for prostate cancer. Br J Radiol. 2009;82:1019\u201326. https:\/\/doi.org\/10.1259\/bjr\/65939531.","journal-title":"Br J Radiol"},{"key":"4581_CR6","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630\u201342. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.002.","journal-title":"Eur Urol"},{"key":"4581_CR7","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1097\/01.ju.0000024925.67014.21","volume":"168","author":"C Kwak","year":"2002","unstructured":"Kwak C, Jeong SJ, Park MS, Lee E, Lee SE. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol. 2002;168:995\u20131000. https:\/\/doi.org\/10.1097\/01.ju.0000024925.67014.21.","journal-title":"J Urol"},{"key":"4581_CR8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1464-410X.2009.08345.x","volume":"103","author":"JM Fitzpatrick","year":"2009","unstructured":"Fitzpatrick JM, Banu E, Oudard S. Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int. 2009;103:578\u201387. https:\/\/doi.org\/10.1111\/j.1464-410X.2009.08345.x.","journal-title":"BJU Int"},{"key":"4581_CR9","doi-asserted-by":"publisher","first-page":"W645","DOI":"10.2214\/ajr.13.12277","volume":"203","author":"AY Kim","year":"2014","unstructured":"Kim AY, Kim CK, Park SY, Park BK. Diffusion-weighted imaging to evaluate for changes from androgen deprivation therapy in prostate cancer. AJR Am J Roentgenol. 2014;203:W645\u201350. https:\/\/doi.org\/10.2214\/ajr.13.12277.","journal-title":"AJR Am J Roentgenol"},{"key":"4581_CR10","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1007\/s00330-015-3688-1","volume":"25","author":"AM Hotker","year":"2015","unstructured":"Hotker AM, Mazaheri Y, Zheng J, Moskowitz CS, Berkowitz J, Lantos JE, et al. Prostate cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI. Eur Radiol. 2015;25:2665\u201372. https:\/\/doi.org\/10.1007\/s00330-015-3688-1.","journal-title":"Eur Radiol"},{"key":"4581_CR11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","volume":"52","author":"SD Sweat","year":"1998","unstructured":"Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637\u201340.","journal-title":"Urology."},{"key":"4581_CR12","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00259-008-0716-2","volume":"35","author":"G Giovacchini","year":"2008","unstructured":"Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [(11)C]choline uptake with PET\/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging. 2008;35:1065\u201373. https:\/\/doi.org\/10.1007\/s00259-008-0716-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4581_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13550-015-0145-8","volume":"5","author":"B Meller","year":"2015","unstructured":"Meller B, Bremmer F, Sahlmann CO, Hijazi S, Bouter C, Trojan L, et al. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 2015;5:66. https:\/\/doi.org\/10.1186\/s13550-015-0145-8.","journal-title":"EJNMMI Res"},{"key":"4581_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2967\/jnumed.116.181800","volume":"58","author":"TA Hope","year":"2017","unstructured":"Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, et al. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med. 2017;58:81\u20134. https:\/\/doi.org\/10.2967\/jnumed.116.181800.","journal-title":"J Nucl Med"},{"key":"4581_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197\u2013209. https:\/\/doi.org\/10.1007\/s00259-014-2949-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4581_CR16","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","volume":"44","author":"A Afshar-Oromieh","year":"2017","unstructured":"Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44:1258\u201368. https:\/\/doi.org\/10.1007\/s00259-017-3711-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4581_CR17","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s00259-018-4079-z","volume":"45","author":"A Afshar-Oromieh","year":"2018","unstructured":"Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, et al. Impact of long-term androgen deprivation therapy on PSMA ligand PET\/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:2045\u201354. https:\/\/doi.org\/10.1007\/s00259-018-4079-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"4581_CR18","doi-asserted-by":"publisher","first-page":"950","DOI":"10.2967\/jnumed.118.223099","volume":"60","author":"Louise Emmett","year":"2018","unstructured":"Emmett LM, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, et al. Rapid modulation of PSMA expression by androgen deprivation: serial (68)Ga PSMA-11 PET in men with hormone sensitive and castrate resistant prostate cancer commencing androgen blockade. J Nucl Med. 2018. https:\/\/doi.org\/10.2967\/jnumed.118.223099.","journal-title":"Journal of Nuclear Medicine"},{"key":"4581_CR19","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0022-5347(01)64230-7","volume":"158","author":"AV D'Amico","year":"1997","unstructured":"D'Amico AV, Whittington R, Schultz D, Malkowicz SB, Tomaszewski JE, Wein A. Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol. 1997;158:1422\u20136.","journal-title":"J Urol"},{"issue":"Suppl 1","key":"4581_CR20","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S\u201350S. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","journal-title":"J Nucl Med"},{"key":"4581_CR21","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00259-011-1867-0","volume":"38","author":"C Fuccio","year":"2011","unstructured":"Fuccio C, Schiavina R, Castellucci P, Rubello D, Martorana G, Celli M, et al. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET\/CT study. Eur J Nucl Med Mol Imaging. 2011;38:1985\u20139. https:\/\/doi.org\/10.1007\/s00259-011-1867-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4581_CR22","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s00259-014-2720-z","volume":"41","author":"S Chondrogiannis","year":"2014","unstructured":"Chondrogiannis S, Marzola MC, Ferretti A, Grassetto G, Maffione AM, Rampin L, et al. Is the detection rate of 18F-choline PET\/CT influenced by androgen-deprivation therapy? Eur J Nucl Med Mol Imaging. 2014;41:1293\u2013300. https:\/\/doi.org\/10.1007\/s00259-014-2720-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4581_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/BF02825824","volume":"73","author":"A Bansal","year":"2006","unstructured":"Bansal A, Singhi SC, Jayashree M. Penicillin and gentamicin therapy vs amoxicillin\/clavulanate in severe hypoxemic pneumonia. Indian J Pediatr. 2006;73:305\u20139.","journal-title":"Indian J Pediatr"},{"key":"4581_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/pros.21241","volume":"71","author":"S Minner","year":"2011","unstructured":"Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate. 2011;71:281\u20138. https:\/\/doi.org\/10.1002\/pros.21241.","journal-title":"Prostate."},{"key":"4581_CR25","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1007\/s00259-017-3752-y","volume":"44","author":"C Obek","year":"2017","unstructured":"Obek C, Doganca T, Demirci E, Ocak M, Kural AR, Yildirim A, et al. The accuracy of (68)Ga-PSMA PET\/CT in primary lymph node staging in high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1806\u201312. https:\/\/doi.org\/10.1007\/s00259-017-3752-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4581_CR26","doi-asserted-by":"publisher","first-page":"9578","DOI":"10.1073\/pnas.1106383108","volume":"108","author":"MJ Evans","year":"2011","unstructured":"Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011;108:9578\u201382. https:\/\/doi.org\/10.1073\/pnas.1106383108.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4581_CR27","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s13139-018-0548-3","volume":"52","author":"M Gupta","year":"2018","unstructured":"Gupta M, Choudhury PS, Rawal S, Goel HC, Rao SA. Evaluation of RECIST, PERCIST, EORTC, and MDA criteria for assessing treatment response with Ga68-PSMA PET-CT in metastatic prostate cancer patient with biochemical progression: a comparative study. Nucl Med Mol Imaging. 2018;52:420\u20139. https:\/\/doi.org\/10.1007\/s13139-018-0548-3.","journal-title":"Nucl Med Mol Imaging"},{"key":"4581_CR28","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s00259-018-4042-z","volume":"45","author":"C Schmidkonz","year":"2018","unstructured":"Schmidkonz C, Cordes M, Schmidt D, Bauerle T, Goetz TI, Beck M, et al. (68)Ga-PSMA-11 PET\/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:1862\u201372. https:\/\/doi.org\/10.1007\/s00259-018-4042-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4581_CR29","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.2967\/jnumed.117.193581","volume":"58","author":"S Schmuck","year":"2017","unstructured":"Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, et al. Initial experience with volumetric (68)Ga-PSMA I&T PET\/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med. 2017;58:1962\u20138. https:\/\/doi.org\/10.2967\/jnumed.117.193581.","journal-title":"J Nucl Med"},{"key":"4581_CR30","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.2967\/jnumed.117.190314","volume":"58","author":"SA Koerber","year":"2017","unstructured":"Koerber SA, Utzinger MT, Kratochwil C, Kesch C, Haefner MF, Katayama S, et al. (68)Ga-PSMA-11 PET\/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters. J Nucl Med. 2017;58:1943, 8. https:\/\/doi.org\/10.2967\/jnumed.117.190314.","journal-title":"J Nucl Med"},{"key":"4581_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/ERC-18-0226","volume":"26","author":"MK Bakht","year":"2018","unstructured":"Bakht MK, Derecichei I, Li Y, Ferraiuolo RM, Dunning M, Oh SW, et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer. 2018;26:131\u201346. https:\/\/doi.org\/10.1530\/ERC-18-0226.","journal-title":"Endocr Relat Cancer"},{"key":"4581_CR32","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/j.1442-2042.2009.02329.x","volume":"16","author":"SC Park","year":"2009","unstructured":"Park SC, Rim JS, Choi HY, Kim CS, Hong SJ, Kim WJ, et al. Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: predictive factors. Int J Urol. 2009;16:670\u20135. https:\/\/doi.org\/10.1111\/j.1442-2042.2009.02329.x.","journal-title":"Int J Urol"},{"key":"4581_CR33","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163\u201377. https:\/\/doi.org\/10.1016\/S0140-6736(15)01037-5.","journal-title":"Lancet."},{"key":"4581_CR34","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1704174.","journal-title":"N Engl J Med"},{"key":"4581_CR35","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36:1080\u20137. https:\/\/doi.org\/10.1200\/JCO.2017.75.3657.","journal-title":"J Clin Oncol"},{"key":"4581_CR36","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.nucmedbio.2006.08.002","volume":"33","author":"T Hara","year":"2006","unstructured":"Hara T, Bansal A, DeGrado TR. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells. Nucl Med Biol. 2006;33:977\u201384. https:\/\/doi.org\/10.1016\/j.nucmedbio.2006.08.002.","journal-title":"Nucl Med Biol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04581-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04581-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04581-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:12:23Z","timestamp":1605312743000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04581-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["4581"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04581-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,15]]},"assertion":[{"value":"29 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest. The authors alone are responsible for the content and writing of the paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}